CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 38 result(s)

Abuse and Misuse Potential of Drugs for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Evidence

Last Updated: August 22, 2013
Result type: Reports
Product Line: Rapid Response
Research Type: Drug

Report in Brief Context
Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioural disorder characterized by inappropriate levels of inattention, hyperactivity, and impulsivity. In Canada, 5% to 12% of school-aged children have ADHD. About 80% of children diagnosed with this condition ...

  • Project Number: RC0472-000

Tricyclic Antidepressants, Clonidine, Venlafaxine, and Modafinil for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: A Review of the Clinical Evidence

Last Updated: March 21, 2013
Result type: Reports
Product Line: Rapid Response

Report in Brief Context
Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioural disorder characterized by inappropriate levels of inattention, hyperactivity, and impulsivity. It manifests in childhood and continues into adulthood, resulting in functional impairment in academic, fami...

  • Project Number: RC0440-000